drugset / Trial / NCT01964404
Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?
Phase 1
Completed
263 enrolled
Dartmouth-Hitchcock Medical Center
Columbia University · collabHarvard Medical School (HMS and HSDM) · collabMassachusetts General Hospital · collabMassachusetts Institute of Technology · collabNathan Kline Institute for Psychiatric Research · collabNational Institute on Drug Abuse (NIDA) · collabUniversity of Vermont · collab
RandomizedParallel-groupQuadruple-blindBasic science
Summary
In this translational research proposal, based on our formulation, we seek to confirm and expand upon data obtained in our pilot study suggesting that cannabis and the cannabinoid agonist dronabinol, given in low dose to patients with schizophrenia and co-occurring cannabis use disorder, will in fact ameliorate the brain reward circuit dysregulation in these patients and, thereby, provide evidence in support of the role of cannabis as a "self-medication" agent for them.
Timeline
- Start
- 2014-07
- Primary completion
- 2021-09-18
- Completion
- 2021-09-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabis | Traditional medicine (herbal / TCM) | — | Other |
| Subject | Dronabinol | Other / unclassified | 15 mg | Oral |